PRESTIGE CONSUMER HEALTHCARE (PBH) Fundamental Analysis & Valuation
NYSE:PBH • US74112D1019
66.91 USD
-0.28 (-0.42%)
Last: Mar 9, 2026, 09:30 AM
This PBH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
PBH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. PBH scores excellent on profitability, but there are some minor concerns on its financial health. PBH has a valuation in line with the averages, but it does not seem to be growing.
1. PBH Profitability Analysis
1.1 Basic Checks
- PBH had positive earnings in the past year.
- In the past year PBH had a positive cash flow from operations.
- Of the past 5 years PBH 4 years were profitable.
- PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of PBH (5.34%) is better than 87.05% of its industry peers.
- Looking at the Return On Equity, with a value of 10.19%, PBH belongs to the top of the industry, outperforming 86.01% of the companies in the same industry.
- PBH's Return On Invested Capital of 7.55% is amongst the best of the industry. PBH outperforms 86.53% of its industry peers.
- PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is below the industry average of 13.08%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.34% | ||
| ROE | 10.19% | ||
| ROIC | 7.55% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- PBH's Profit Margin of 16.90% is amongst the best of the industry. PBH outperforms 89.64% of its industry peers.
- PBH's Profit Margin has improved in the last couple of years.
- PBH has a Operating Margin of 30.34%. This is amongst the best in the industry. PBH outperforms 93.78% of its industry peers.
- In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
- With a decent Gross Margin value of 56.12%, PBH is doing good in the industry, outperforming 67.88% of the companies in the same industry.
- PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.34% | ||
| PM (TTM) | 16.9% | ||
| GM | 56.12% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. PBH Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
- The number of shares outstanding for PBH has been reduced compared to 1 year ago.
- PBH has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
- PBH has an Altman-Z score of 2.56. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.56, PBH is in the better half of the industry, outperforming 67.36% of the companies in the same industry.
- The Debt to FCF ratio of PBH is 3.95, which is a good value as it means it would take PBH, 3.95 years of fcf income to pay off all of its debts.
- PBH's Debt to FCF ratio of 3.95 is amongst the best of the industry. PBH outperforms 87.56% of its industry peers.
- A Debt/Equity ratio of 0.58 indicates that PBH is somewhat dependend on debt financing.
- PBH has a Debt to Equity ratio of 0.58. This is in the lower half of the industry: PBH underperforms 64.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 3.95 | ||
| Altman-Z | 2.56 |
ROIC/WACC0.85
WACC8.86%
2.3 Liquidity
- PBH has a Current Ratio of 3.11. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- PBH has a Current ratio of 3.11. This is comparable to the rest of the industry: PBH outperforms 54.40% of its industry peers.
- A Quick Ratio of 1.93 indicates that PBH should not have too much problems paying its short term obligations.
- The Quick ratio of PBH (1.93) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.11 | ||
| Quick Ratio | 1.93 |
3. PBH Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 6.92% over the past year.
- PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
- The Revenue has decreased by -1.31% in the past year.
- PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
3.2 Future
- The Earnings Per Share is expected to grow by 4.28% on average over the next years.
- The Revenue is expected to grow by 0.71% on average over the next years.
EPS Next Y1.25%
EPS Next 2Y3.42%
EPS Next 3Y3.88%
EPS Next 5Y4.28%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. PBH Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 14.94, which indicates a correct valuation of PBH.
- PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.05% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.29, PBH is valued a bit cheaper.
- PBH is valuated correctly with a Price/Forward Earnings ratio of 13.81.
- 84.46% of the companies in the same industry are more expensive than PBH, based on the Price/Forward Earnings ratio.
- PBH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.60, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.94 | ||
| Fwd PE | 13.81 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 86.53% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 89.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.85 | ||
| EV/EBITDA | 11.43 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)11.94
PEG (5Y)1.68
EPS Next 2Y3.42%
EPS Next 3Y3.88%
5. PBH Dividend Analysis
5.1 Amount
- PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PBH Fundamentals: All Metrics, Ratios and Statistics
NYSE:PBH (3/9/2026, 9:30:11 AM)
66.91
-0.28 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)05-06 2026-05-06/bmo
Inst Owners110.56%
Inst Owner Change0.31%
Ins Owners1.33%
Ins Owner Change-0.48%
Market Cap3.17B
Revenue(TTM)1.10B
Net Income(TTM)186.50M
Analysts84
Price Target78.95 (17.99%)
Short Float %4.31%
Short Ratio4.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.91%
Min EPS beat(2)-1.36%
Max EPS beat(2)9.18%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)4
Avg EPS beat(8)-0.63%
EPS beat(12)6
Avg EPS beat(12)-46.73%
EPS beat(16)10
Avg EPS beat(16)-34.55%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)5.55%
Revenue beat(4)2
Avg Revenue beat(4)0.29%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)1.18%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-1.05%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.38%
Revenue NQ rev (1m)-2.24%
Revenue NQ rev (3m)-2.24%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.94 | ||
| Fwd PE | 13.81 | ||
| P/S | 2.87 | ||
| P/FCF | 11.85 | ||
| P/OCF | 11.45 | ||
| P/B | 1.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.43 |
EPS(TTM)4.48
EY6.7%
EPS(NY)4.85
Fwd EY7.24%
FCF(TTM)5.65
FCFY8.44%
OCF(TTM)5.85
OCFY8.74%
SpS23.32
BVpS38.66
TBVpS-22.26
PEG (NY)11.94
PEG (5Y)1.68
Graham Number62.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.34% | ||
| ROE | 10.19% | ||
| ROCE | 9.98% | ||
| ROIC | 7.55% | ||
| ROICexc | 7.69% | ||
| ROICexgc | 61.8% | ||
| OM | 30.34% | ||
| PM (TTM) | 16.9% | ||
| GM | 56.12% | ||
| FCFM | 24.21% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score5
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 3.95 | ||
| Debt/EBITDA | 2.88 | ||
| Cap/Depr | 31.31% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 75.79% | ||
| Profit Quality | 143.26% | ||
| Current Ratio | 3.11 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 2.56 |
F-Score5
WACC8.86%
ROIC/WACC0.85
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.25%
EPS Next 2Y3.42%
EPS Next 3Y3.88%
EPS Next 5Y4.28%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
EBIT growth 1Y1.3%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year5.29%
EBIT Next 3Y3.49%
EBIT Next 5Y2.82%
FCF growth 1Y15.15%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y14.78%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.25% in the next year.